Efficiency of Glaucoma Drug Regulation in 5 European Countries: A 1995-2006 Longitudinal Prescription Analysis
Berdeaux, Gilles; Le Pen, Claude; De Natale, Renato (2011), Efficiency of Glaucoma Drug Regulation in 5 European Countries: A 1995-2006 Longitudinal Prescription Analysis, Journal of Glaucoma, 20, 4, p. 234–239. http://dx.doi.org/10.1097/IJG.0b013e3181e0791c
TypeArticle accepté pour publication ou publié
Nom de la revueJournal of Glaucoma
MétadonnéesAfficher la notice complète
Résumé (EN)Purpose: To compare the evolution of prostaglandin analog (PGA) and β-blocker (BB) prescriptions across 5 European countries. Methods: Data were extracted from various sources: (1) IMS data for France, Germany, Italy, Spain, and the United Kingdom, (2) glaucoma-treated patients from the United Kingdom General Practice Research Database (UK-GPRD), (3) prescriptions delivered by the territorial pharmaceutical service of Monselice of the Padova region (Italy). Drugs were grouped into 3 classes: PGAs, BBs, and other drugs. Yearly market shares were calculated. Treatment persistence survival curves were estimated for Italian and UK data, and the 3 drug groups were compared using the Cochran Mantel Haenszel test. Results: According to Padova data, BBs decreased in market share, whereas PGAs increased. A linear extrapolation of these market shares, based on 1998 to 2003 data, predicted that the 2 curves should cross in 2005, a prediction reinforced by the European Medicines Agency authorization (2002) of PGAs as first-line glaucoma treatments. That this did not occur may be explained by Italy's refusal to reimburse PGAs as first-line therapy. IMS data identified Italy and Germany as 2 countries in which BBs are still more frequently prescribed than PGAs. Treatment persistence with PGAs as monotherapy, in PGA-naive patients, was longer than for BBs according to both Padova and UK-GPRD data. This held true for both first-line and second-line PGA prescriptions (UK-GPRD); the persistence of second-line PGA equalled first-line BB treatment. Conclusion: Health care regulations impacted upon glaucoma prescribing and may be one of the reasons for different annual evolution rates of PGA and BB prescriptions.
Mots-clésHealth care regulations
Affichage des éléments liés par titre et auteur.
Temporary use authorizations : the economic and clinical future of drugs used in the french compassionate program Le Pen, Claude; Parent de Curzon, Olivier; Paubel, Pascal; Sinègre, Martine; Degrassat-Théas, Albane (2011) Article accepté pour publication ou publié
Hospital Reimbursement Price Cap for Cancer Drugs: the French experience in controlling hospital drug expenditures Degrassat-Théas, Albane; Bensadon, M.; Rieu, C.; Angalakuditi, M.; Le Pen, Claude; Paubel, Pascal (2012) Article accepté pour publication ou publié